Potassium chloride
- Generic Name
- Potassium chloride
- Brand Names
- Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Pokonza, Prismasol, Procalamine 3, Ringers, Selectbag One, Suflave, Tis-U-sol
- Drug Type
- Small Molecule
- Chemical Formula
- ClK
- CAS Number
- 7447-40-7
- Unique Ingredient Identifier
- 660YQ98I10
- Background
A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.
...
- Indication
For use as an electrolyte replenisher and in the treatment of hypokalemia.
- Associated Conditions
- Dehydration, Dry Mouth, Hypokalemia, Hypotonic Dehydration, Hypovolaemia, Isotonic Dehydration, Markedly Reduced Food Intake, Metabolic Acidosis, Hypodermoclysis, Mild Metabolic acidosis, Mild, moderate Metabolic Acidosis, Ocular edema
- Associated Therapies
- Acid- Base Balance, Bowel preparation therapy, Electrolyte replacement, Fluid replacement therapy, Haemofiltration, Hemodialysis Treatment, Parenteral Nutrition, Parenteral rehydration therapy, Plasma Volume Replacement, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy
VCU startup grabs military attention, funding
A Virginia Commonwealth University research scientist's discovery of a drug, PM-208, which could revolutionize treatment for massive blood loss injuries, receives $1.8 million grant from the U.S. Air Force, bringing total military support to $7 million. PM-208, an intravenous infusion of polyethylene glycol, prevents ischemic injury by pulling water into capillaries, significantly extending survivability in animal models.
New Psychiatric Technique Asks Schizophrenics to Engage in Dialogue With the Voices
Researchers use 'avatar therapy' to treat psychosis by creating digital avatars representing inner voices, showing promising results in clinical trials, including reducing auditory hallucinations and suicidal thoughts.
Paclitaxel- or sirolimus-coated balloons used for ArterioVEnous fistulas-2 (PAVE-2)
Multicentre RCT comparing paclitaxel-coated, sirolimus-coated balloons to uncoated control in 642 patients with AVF, over 3 years, followed for 1 year. Primary endpoint: time to loss of treatment segment primary patency (TSPP). Secondary endpoints: time to loss of primary patency at any treatment segment, access circuit primary patency, AVF abandonment, total interventions, adverse events, patient quality of life, intima-media thickness, and degree of stenosis. Randomisation minimises by site, previous intervention, AVF location, and treatment segments. Follow-up every 3 months for 1 year, with ultrasound assessments at selected sites. Measures to avoid bias include blinded follow-up and primary endpoint adjudication by independent radiologists. Safety assessed through SAEs related to treatment or access circuit, reported within 24 hours.
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction
Bausch Health to present Xifaxan monotherapy vs. lactulose monotherapy for OHE recurrence risk reduction and mortality at ACG 2024, along with data on Xifaxan's impact on rehospitalizations in commercial and Medicare patients, and Plenvu's efficacy as a bowel preparation medication.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath